Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access
Humacyte presented research at the VASA 2026 Symposium demonstrating that its ATEV product maintains structural integrity and exhibits self-repair via smooth muscle cell repopulation after repeated cannulation. Histological analysis of explants up to 5.5 years post-implantation showed functional tissue remodeling, including capillary ingrowth and organized collagen deposition, alongside greater resistance to bacterial infection compared to ePTFE grafts.
Key figures
- Drug Name
- ATEV (acellular tissue engineered vessel)
- Phase Of Trial
- Phase 3
- Next data date
- June 11, 2026
- Explant duration
- 5.5 years
- Annual cannulations
- 300+
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.